Walter Stummer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial

ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Thomas bauerKathleen noonan gerrit siegersSteffen schusterBen orzelekVerena cosciaUmwelt gmbWalter stummerReinhard zeidlerDeutsches forschungszentrumHelmholtz associationNuclear medicineCorporate communicationsUniversity hospitalDepartment of neurosurgeryNovel therapeutic approachHelmholtz munich

ITM, Helmholtz Munich and University Hospital Münster

A Novel Therapeutic Approach to Treatment using ITM-31 Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of.

Ben orzelekSteffen schusterKathleen noonan gerrit siegersThomas bauerReinhard zeidlerDeutsches forschungszentrumWalter stummerVerena cosciaUmwelt gmbNuclear medicineDepartment of neurosurgeryUniversity hospitalCorporate communicationsHelmholtz associationNovel therapeutic approachHelmholtz munich

ITM, Helmholtz Munich and University Hospital Münster

Garching/Munich, Munich and Münster, Germany, March 13, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company,.

Reinhard zeidlerBen orzelekDeutsches forschungszentrumWalter stummerThomas bauerVerena cosciaSteffen schusterJulia hofmann svenjaUmwelt gmbDepartment of neurosurgeryUniversity hospitalNuclear medicineCorporate communicationsHelmholtz associationTargeted radionuclide therapyHelmholtz munich

ITM Isotope Technologies Munich SE: ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma

Garching/Munich, Munich and Münster, Germany, March 13, 2023 - ITM Isotope Technologies Munich SEand the Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster today announced

Dennis riedlReinhard zeidlerBen orzelekWalter stummerThomas bauerVerena cosciaSteffen schusterJulia hofmann svenjaDepartment of neurosurgeryUniversity hospitalNuclear medicineCorporate communicationsHelmholtz associationTechnologies munichTargeted radionuclide therapyHelmholtz munich

First-in-human clinical trial for treatment for Brain Cancer

Alpheus™ Medical, Inc, a privately held company developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers, today announced the

Vijay agarwalRoger stuppDavid reardon harvard medical schoolWalter stummer university hospitalDana farber cancer instituteMathias senge trinity college dublinScientific advisory boardNorthwestern university feinberg schoolDavid reardonHarvard medical schoolWalter stummerMathias sengeTrinity college dublinAlpheus medicalMalnati brain tumor instituteLurie comprehensive cancer center